Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Update

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totaling 133,590 shares, an increase of 2,380.8% from the December 31st total of 5,385 shares. Approximately 8.4% of the shares of the stock are short sold. Based on an average daily volume of 2,064,105 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily volume of 2,064,105 shares, the days-to-cover ratio is currently 0.1 days. Approximately 8.4% of the shares of the stock are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cardio Diagnostics in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Cardio Diagnostics currently has a consensus rating of “Sell”.

Cardio Diagnostics Stock Performance

Shares of NASDAQ CDIO traded up $0.03 during trading on Tuesday, hitting $1.84. The company had a trading volume of 49,675 shares, compared to its average volume of 1,143,069. Cardio Diagnostics has a 52 week low of $1.64 and a 52 week high of $20.55. The business’s 50-day moving average is $2.77 and its 200 day moving average is $3.56. The company has a market cap of $3.37 million, a P/E ratio of -0.49 and a beta of 2.94.

Cardio Diagnostics (NASDAQ:CDIO) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.80) by $0.82. The business had revenue of $0.00 million during the quarter, compared to analyst estimates of $0.15 million. Cardio Diagnostics had a negative return on equity of 67.51% and a negative net margin of 39,674.18%. On average, research analysts expect that Cardio Diagnostics will post -0.55 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cardio Diagnostics stock. Citadel Advisors LLC bought a new position in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 19,520 shares of the company’s stock, valued at approximately $79,000. Citadel Advisors LLC owned approximately 1.07% of Cardio Diagnostics at the end of the most recent reporting period. Institutional investors and hedge funds own 8.06% of the company’s stock.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.